RecruitingOBSERVATIONAL

New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

This research is focused on finding new treatments for BK virus (BKV) infections, which can be a serious issue for people who have received organ transplants. Right now, there isn't a specific medication designed to fight BKV. This means that doctors really need better options to help prevent and treat this infection. The study aims to look into a new way of treating BKV using special proteins called monoclonal antibodies. These antibodies are designed to target and fight off the virus. By taking part, you could help researchers develop effective new treatments that could one day benefit many transplant patients.

At a glance

Status

Recruiting

Sponsor

University Hospital, Strasbourg, France

Enrolment target

100

Start

05 Sep 2022

Estimated completion

01 Dec 2025

BK Virus Infection

What is this study about?

If you've had an organ transplant, you might know about the BK virus (BKV). It's a common virus that can cause problems for people after a transplant because their immune system is weaker due to the medicines they take. When BKV flares up, it can sometimes harm the new organ, which is a big concern for doctors and patients alike.

Currently, we don't have a specific medicine that directly targets and stops the BK virus. This means doctors have to rely on other methods, like reducing the patient's immune-suppressing medicines, which can have their own set of risks. Because of this, there's a strong need to find better and safer ways to either prevent BKV infections from becoming serious or to treat them effectively once they start.

This study is looking into a new and promising approach using something called monoclonal antibodies. These are special proteins made in a lab that are designed to find and attack specific targets, in this case, the BK virus. The hope is that these antibodies could act like a precise shield or weapon against the virus, offering a new way to keep transplant patients healthy and protect their new organs. By trying out these new treatments, researchers hope to improve care for anyone affected by the BK virus.

Key takeaways

New study for BK virus in transplant patients.
Aims to test new antibody treatments.
No specific BK virus medicine currently exists.
Looking for adults with active BK virus.
Could help develop future treatments.
Participation involves close monitoring.

Who may be eligible?

To join this study, you need to be an adult, which means you must be 18 years old or older. You also need to have tested positive for the BK virus. Importantly, you must be comfortable and willing to take part in research studies and understand what it involves.

There are some reasons why you might not be able to join. For example, if someone else legally makes decisions about your care, or if you've expressed that you don't want to be part of research, you wouldn't be eligible. Also, if you are currently in prison or detained, you wouldn't be able to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I 18 years old or older?
Have I been told I have the BK virus?
Am I happy to take part in research?
Am I able to make my own decisions about my health?

Answer every question to see your result.

What does participation involve?

The specific details of what taking part involves aren't fully described here. However, generally in studies like this, you might have regular visits to a clinic or hospital where the research team will monitor your health. This could include things like blood tests, check-ups, and perhaps scans. If the new antibody treatment is given, it might be through an injection or an infusion (a drip). You'll be closely watched to see how you respond to the treatment and for any side effects. There would also likely be follow-up appointments after the main treatment period to see how you're doing in the long term. The total duration of your participation would be explained before you agree to join.

Potential risks and benefits

Taking part in this study could potentially offer you access to a new treatment for BK virus that isn't widely available yet. If successful, this new therapy could be more effective or have fewer side effects than current approaches. However, all medical treatments carry some risks. There might be side effects from the new antibody treatment that aren't fully known yet, or it might not work as hoped. You will be closely monitored for any reactions. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Service de Virologie - CHU Strasbourg - France
Verified postcode
Strasbourg, France· Recruiting

Common questions

What is the BK virus?

The BK virus is a common virus that usually doesn't cause problems in healthy people. However, if your immune system is weaker, often after an organ transplant, it can become active and cause illness or harm to the transplant organ.

Why is this study important?

This study is important because currently, there isn't a specific medicine to treat the BK virus. Researchers are looking for new treatments, like these antibodies, to better protect organ transplant patients.

What are monoclonal antibodies?

Monoclonal antibodies are special proteins made in a lab. They are designed to specifically target and fight off things like viruses or bacteria in your body, acting a bit like your own immune system.

Will this new treatment cure my BK virus?

The study aims to see if this new treatment can effectively fight the BK virus. It's a new approach, and the goal is to find better ways to manage or treat the infection, but a 'cure' isn't guaranteed at this stage.

Does this study involve surgery?

Based on the information, this study focuses on a new antibody treatment, likely given through injections or a drip, not surgery.

How to find out more

Anne-Sophie U GEY

anne-sophie.gey@chru-strasbourg.fr +33 388116684 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.